A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 1, 2013, Pages 52-61

  Lindsay, J O ^a   Chipperfield, R ^b   Giles, A ^c   Wheeler, C ^b   Orchard, T ^d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Merck Sharp & Dohme Limited   (United Kingdom)

^c OXFORD PHARMAGENESIS LTD   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MESALAZINE; PREDNISOLONE;

ABSCESS DRAINAGE; ADULT; AGED; ANAPHYLAXIS; ANUS FISTULA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BRONCHITIS; CELLULITIS; CLINICAL EFFECTIVENESS; COLON RESECTION; COST CONTROL; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INDUCED CANCER; DRUG OVERDOSE; DYSPNEA; ELECTIVE SURGERY; FEMALE; HEALTH CARE UTILIZATION; HEART PALPITATION; HERPES ZOSTER; HERPES ZOSTER MENINGITIS; HOSPITALIZATION; HUMAN; ILEOSTOMY; INFECTION; KIDNEY CANCER; KIDNEY FAILURE; LIVER ABSCESS; LIVER METASTASIS; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERIANAL ABSCESS; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSIS; RECTUM CANCER; RETROSPECTIVE STUDY; SEPSIS; UNITED KINGDOM; UTERINE CERVIX TUMOR; VIRUS MENINGITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; CROHN DISEASE; DELIVERY OF HEALTH CARE; FEMALE; GASTROINTESTINAL AGENTS; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878792575     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12339     Document Type: Article

References (34)

1. Dretzke J, Edlin R, Round J, et al,. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess 2011; 15: 1-244.
2. Vermeire S, van Assche G, Rutgeerts P,. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3-12.
3. Blondel-Kucharski F, Chircop C, Marquis P, et al,. Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001; 96: 2915-20.
4. Carter MJ, Lobo AJ, Travis SP,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl. 5): V1-16.
5. Carter CT, Waters HC, Smith DB,. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. Adv Ther 2011; 28: 671-83.
6. Munkholm P, Langholz E, Davidsen M, Binder V,. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
7. Sprakes MB, Ford AC, Suares NC, et al,. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther 2010; 32: 1357-63.
8. Buchanan J, Wordsworth S, Ahmad T, et al,. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis 2011; 5: 301-16.
9. Bassi A, Dodd S, Williamson P, Bodger K,. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471-8.
10. Cohen RD, Waters HC, Tang B, Rahman MI,. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis 2008; 14: 1707-14.
11. Jewell DP, Satsangi J, Lobo A, et al,. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17: 1047-52.
12. Loomes DE, Teshima C, Jacobs P, Fedorak RN,. Health care resource use and costs in Crohn's disease before and after infliximab therapy. Can J Gastroenterol 2011; 25: 497-502.
13. The impact of inflammatory bowel disease in Canada: 2012 Final Report and Recommendations. Crohn's and Colitis Foundation of Canada. Available at: http://www.isupportibd.ca/pdf/ccfc-ibd-impact-report-2012.pdf.
14. Dave M, Loftus EV Jr,. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) 2012; 8: 29-38.
15. McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG,. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2012; (12): CD003459.
16. Remicade Summary of Product Characteristics. Last updated: 06 January 2013. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000240/WC500050888.pdf.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
18. Rutgeerts P, Van Assche G, Vermeire S,. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.
19. Sands BE, Anderson FH, Bernstein CN, et al,. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
20. Schnitzler F, Fidder H, Ferrante M, et al,. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
21. Infliximab (review) and adalimumab for the treatment of Crohn's disease. 2011. National Institute of Health and Clinical Excellence Technology Appraisal Guidance 187 (includes a review of NICE technology appraisal guidance 40). Available at: http://www.nice.org.uk/nicemedia/live/12985/48552/48552.pdf.
22. Satsangi J, Silverberg MS, Vermeire S, Colombel JF,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
23. Curtis L,. Personal Social Services Research Unit. Unit costs of health and social care. 2009. Available at: http://www.pssru.ac.uk/project-pages/unit- costs/2009/index.php.
24. National Schedule of Reference Costs Year: '2008-09'-National Health Service Trusts Healthcare Research Group Data. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-111591.
25. British National Formulary. BNF. Available at: http://www.bnf.org/bnf/ index.htm.
26. Bernell O, Lapidus A, Hellers G,. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45.
27. Osterman MT, Lichtenstein GR,. Infliximab in fistulizing Crohn's disease. Gastroenterol Clin North Am 2006; 35: 795-820.
28. Mylonakis E, Katsios C, Godevenos D, Nousias B, Kappas AM,. Quality of life of patients after surgical treatment of anal fistula; the role of anal manometry. Colorectal Dis 2001; 3: 417-21.
29. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE,. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9.
30. Feagan BG, Panaccione R, Sandborn WJ, et al,. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9.
31. Taxonera C, Rodrigo L, Casellas F, et al,. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009; 43: 950-6.
32. Lim WC, Hanauer S,. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2010; (12): CD008870.
33. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
34. Koelewijn C, Schrijvers A, Oldenburg B,. Infliximab use in patients with Crohn's disease: quality of life, costs and resource use. Neth J Med 2006; 64: 212-8.